Daicel Pharma synthesizes Regadenoson impurity standards such as Regadenoson Impurity-7, Regadenoson Impurity-2, Regadenoson impurity C, Regadenoson impurity A, Regadenoson impurity D, and Regadenoson Carboxylic Acid impurity. These impurities are essential for Regadenoson quality, effectiveness, safety, and stability. Furthermore, Daicel Pharma synthesizes custom Regadenoson impurities and delivers them globally.
Regadenoson [CAS:313348-27-5] is an adenosine receptor agonist. It helps in coronary vasodilation and myocardial perfusion imaging.
Regadenoson: Use and Commercial Availability
Regadenoson anhydrous is a Cardiac Stress Test Agent in Pharmacology. It is for diagnostic purposes. Rapiscan contains the active substance, Regadenoson, a selective coronary vasodilator. It is a stress agent for radionuclide myocardial perfusion imaging (MPI) for adult patients unable to undergo appropriate exercise stress. This drug is available under the tradename of Lexiscan.
Regadenoson Structure and Mechanism of Action
The chemical name of Regadenoson is 2-[4-[(Methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine. Its chemical formula is C15H18N8O5, and its molecular weight is approximately 390.35 g/mol.
Regadenoson activates the A2A adenosine receptor, causes coronary vasodilation, and raises coronary blood flow (CBF).
Regadenoson Impurities and Synthesis
Regadenoson impurities are chemical compounds that form unintentionally during the production1 or storage of Regadenoson, a medicine used for cardiac stress testing. These impurities might come from raw materials, reagents, intermediates, or degradation products. Regadenoson impurities require strict control and monitoring to assure drug safety, efficacy, and quality, and analytical procedures help identify, quantify, and characterize these impurities.
Daicel Pharma offers a Certificate of Analysis (CoA) for Regadenoson impurity standards Regadenoson impurities such as Regadenoson Impurity-7, Regadenoson Impurity-2, Regadenoson impurity C, Regadenoson impurity A, Regadenoson impurity D, and Regadenoson Carboxylic Acid impurity. Our cGMP-certified analytical laboratory provides Daicel Pharma’s CoA and includes detailed characterization data such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. More characterization details, such as those for 13C-DEPT, can be provided on request. Daicel Pharma specializes in synthesizing Regadenoson impurities and degradation compounds.
Regadenoson impurities are considered during stability testing to assess deterioration and variations in impurity levels over time, assuring the medication's quality and stability throughout its shelf life.
The impact of Regadenoson impurities on bioavailability can vary and may affect the drug's absorption, distribution, metabolism, and excretion, potentially altering its therapeutic efficacy and safety.
Regadenoson impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.